Revenue: As of FY2025 Q3, the actual value is USD 263.6 M, missing the estimate of USD 267.14 M.EPS: As of FY2025 Q3, the actual value is USD 0.22, beating the estimate of USD 0.12.EBIT: As of FY2025 Q3, the actual value is USD 25.1 M.<h3>Home Health Segment</h3><ul><li>Net Service Revenue: $200.5 million for Q3 2025, a slight decrease from $201.0 million in Q3 2024. For the nine months ended September 30, 2025, revenue was $607.0 million, down from $624.4 million in the same period of 2024.</li><li>Cost of Service: $107.7 million for Q3 2025, up from $105.9 million in Q3 2024. For the nine months ended September 30, 2025, costs were $318.3 million, down from $322.7 million in the same period of 2024.</li><li>Segment Adjusted EBITDA: $33.9 million for Q3 2025, down from $36.5 million in Q3 2024. For the nine months ended September 30, 2025, EBITDA was $111.5 million, down from $123.9 million in the same period of 2024.</li></ul><h3>Hospice Segment</h3><ul><li>Net Service Revenue: $63.1 million for Q3 2025, up from $52.6 million in Q3 2024. For the nine months ended September 30, 2025, revenue was $182.6 million, up from $152.2 million in the same period of 2024.</li><li>Cost of Service: $28.1 million for Q3 2025, up from $25.8 million in Q3 2024. For the nine months ended September 30, 2025, costs were $83.2 million, up from $75.0 million in the same period of 2024.</li><li>Segment Adjusted EBITDA: $17.2 million for Q3 2025, up from $10.0 million in Q3 2024. For the nine months ended September 30, 2025, EBITDA was $46.2 million, up from $28.2 million in the same period of 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: $66.3 million for the nine months ended September 30, 2025, compared to $55.3 million in the same period of 2024.</li><li>Investing Cash Flow: $17.6 million provided by investing activities for the nine months ended September 30, 2025, compared to $2.1 million used in the same period of 2024.</li><li>Financing Cash Flow: $55.3 million used in financing activities for the nine months ended September 30, 2025, compared to $35.6 million used in the same period of 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is focusing on cost and operating efficiencies, including a pilot program for advanced clinically based management of visits per episode (VPE) in the Home Health segment, with plans to expand this program to all branches in Q4 2025.</li><li>Pricing and Reimbursement: The company is actively engaged in advocacy efforts in response to the proposed 2026 Home Health Rule, which could result in a significant reduction in reimbursement rates if implemented as proposed.</li></ul>

Enhabit Home Health & Hospice | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 263.6 M